Jazz Historical Income Statement
| JAZZ Stock | USD 125.10 5.86 4.91% |
Historical analysis of Jazz Pharmaceuticals income statement accounts such as Operating Income of 607.5 M or Ebit of 851.3 M can show how well Jazz Pharmaceuticals PLC performed in making a profits. Evaluating Jazz Pharmaceuticals income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Jazz Pharmaceuticals's future profits or losses.
Financial Statement Analysis is much more than just reviewing and examining Jazz Pharmaceuticals PLC latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Jazz Pharmaceuticals PLC is a good buy for the upcoming year.
Jazz |
About Jazz Income Statement Analysis
Jazz Pharmaceuticals PLC Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Jazz Pharmaceuticals shareholders. The income statement also shows Jazz investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).
Jazz Pharmaceuticals Income Statement Chart
Add Fundamental
Other Operating Expenses
Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Jazz Pharmaceuticals PLC. It is also known as Jazz Pharmaceuticals overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.Total Revenue
Total revenue comprises all receipts Jazz Pharmaceuticals PLC generated from the sale of its products or services. The total amount of income generated by the sale of goods or services related to the company's primary operations.Gross Profit
Gross profit is a required income statement account that reflects total revenue of Jazz Pharmaceuticals PLC minus its cost of goods sold. It is profit before Jazz Pharmaceuticals operating expenses, interest payments and taxes. Gross profit is also known as gross margin. The profit a company makes after deducting the costs associated with making and selling its products, or the costs associated with providing its services.Minority Interest
Minority Interest is the portion of a subsidiary corporation stock that is not owned by the parent corporation. The magnitude of the minority interest in the subsidiary company is generally less than 50% of outstanding shares, otherwise the corporation would generally cease to be a subsidiary of the parent. Minority Interest can also be called non-controlling interest.All shareholders of Jazz Pharmaceuticals PLC whose combined shares represent less than 50% of the total outstanding shares issued by Jazz Pharmaceuticals have a minority interest in Jazz Pharmaceuticals.Most accounts from Jazz Pharmaceuticals' income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Jazz Pharmaceuticals PLC current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Jazz Pharmaceuticals PLC. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. At this time, Jazz Pharmaceuticals' Gross Profit is fairly stable compared to the past year. Research Development is likely to rise to about 892.1 M in 2024, despite the fact that Income Tax Expense is likely to grow to (113.9 M).
| 2021 | 2022 | 2023 | 2024 (projected) | Gross Profit | 2.7B | 3.1B | 3.4B | 3.6B | Total Revenue | 3.1B | 3.7B | 3.8B | 4.0B |
Jazz Pharmaceuticals income statement Correlations
Click cells to compare fundamentals
Jazz Pharmaceuticals Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Jazz Pharmaceuticals income statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Interest Expense | 72.3M | 99.7M | 278.8M | 288.2M | 289.4M | 303.9M | |
| Other Operating Expenses | 1.5B | 1.6B | 2.9B | 3.1B | 3.3B | 3.4B | |
| Operating Income | 532.4M | 765.5M | 170.3M | 512.3M | 578.6M | 607.5M | |
| Ebit | 532.4M | 371.4M | 475.3M | (75.7M) | 810.7M | 851.3M | |
| Ebitda | 997.2M | 649.7M | 1.0B | 553.8M | 1.4B | 1.5B | |
| Total Operating Expenses | 1.4B | 1.4B | 2.5B | 2.6B | 3.3B | 3.4B | |
| Net Income | 523.4M | 238.6M | (329.0M) | (214.1M) | 414.8M | 435.6M | |
| Income Tax Expense | (73.2M) | 33.5M | 216.1M | (158.6M) | (119.9M) | (113.9M) | |
| Depreciation And Amortization | 464.8M | 278.3M | 552.5M | 629.5M | 638.7M | 670.6M | |
| Selling General Administrative | 736.9M | 854.2M | 1.5B | 1.4B | 1.3B | 1.4B | |
| Total Revenue | 2.2B | 2.4B | 3.1B | 3.7B | 3.8B | 4.0B | |
| Gross Profit | 2.0B | 2.2B | 2.7B | 3.1B | 3.4B | 3.6B | |
| Research Development | 299.7M | 335.4M | 505.7M | 590.5M | 849.7M | 892.1M | |
| Cost Of Revenue | 127.9M | 148.9M | 440.8M | 540.5M | 435.6M | 457.4M | |
| Income Before Tax | 454.3M | 275.1M | (112.8M) | (372.8M) | 297.9M | 161.9M | |
| Total Other Income Expense Net | (78.1M) | (103.0M) | (283.1M) | (307.3M) | (280.7M) | (266.6M) | |
| Net Income Applicable To Common Shares | 523.4M | 238.6M | (329.7M) | (224.1M) | (201.7M) | (191.6M) | |
| Net Income From Continuing Ops | 523.4M | 241.6M | (329.7M) | (214.1M) | 80.0M | 151.3M | |
| Non Recurring | 85M | 42.9M | 387.4M | 577.8M | 664.5M | 697.7M | |
| Tax Provision | (73.2M) | 33.5M | 216.1M | (158.6M) | (186.9M) | (177.5M) | |
| Net Interest Income | (72.3M) | (99.7M) | (278.8M) | (288.2M) | (293.2M) | (278.6M) | |
| Reconciled Depreciation | 370.2M | 278.3M | 552.5M | 629.5M | 624.2M | 445.7M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Jazz Stock Analysis
When running Jazz Pharmaceuticals' price analysis, check to measure Jazz Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Jazz Pharmaceuticals is operating at the current time. Most of Jazz Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Jazz Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Jazz Pharmaceuticals' price. Additionally, you may evaluate how the addition of Jazz Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.